$CBDL CBD Life Sciences Inc. (CBDL) Announces New Powerful

New Post Public Reply Private Reply Replies (0) Message Board
louied91
113
$CBDL CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy


https://www.accessnewswire.com/newsroom/en/he...-8-1032515

With Delta-8 product revenue continuing to climb, CBDL introduces a lab-tested gummy formulation to meet surging demand in a market projected to exceed $2.1 billion by 2026.

SCOTTSDALE, AZ / ACCESS Newswire / May 28, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising force in the cannabinoid wellness industry, is proud to announce the latest addition to its growing Delta-8 product lineup: a premium, lab-tested Delta-8 THC gummy, developed in-house to ensure consistency, potency, and quality at every step.

Building on the success of its existing Delta-8 offerings, this new gummy marks another strategic milestone in CBDL's mission to dominate the cannabinoid edibles market. Crafted in a controlled lab environment, this new edible is designed for consumers who prioritize quality, effectiveness, and a clean, smooth Delta-8 experience.

"We've already seen strong performance across our Delta-8 line, and this gummy is a direct response to customer demand for more convenient, enjoyable, and effective ways to experience its benefits," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As always, we're delivering a product that's backed by science, produced in-house, and driven by results."

Delta-8 THC: Expanding the Future of Functional Wellness
Unlike traditional Delta-9 THC, Delta-8 offers a milder, clearer psychoactive experience - making it a preferred option for wellness seekers, first-time users, and individuals looking for a balanced high without anxiety.

CBDL's newly formulated Delta-8 gummies are not just about effect - they're designed to deliver real therapeutic value. Below is a breakdown of the core wellness benefits supported by research and consumer feedback:

Pain Relief

• Engages the endocannabinoid system to help regulate pain
• May reduce inflammation that contributes to chronic discomfort

Anxiety & Stress Support

• Natural calming effects to help manage daily stress and reduce anxiety
• Promotes overall mood balance without sedation

Nausea Control

• Anti-emetic potential makes it a powerful option for those undergoing chemotherapy or other nausea-inducing treatments

Appetite Stimulation

• Ideal for individuals with appetite loss or dietary imbalances related to health conditions

Neuroprotective Potential

• Early research suggests Delta-8 THC may contribute to long-term brain health through its interaction with CB1 receptors

Made In-House. Backed by Lab Testing.
Unlike many mass-produced gummies on the market, CBDL maintains full control over every phase - from formulation to packaging - in its in-house manufacturing facility. Each batch is independently lab-tested to guarantee purity, potency, and compliance, giving consumers complete confidence in what they're consuming.

Strategic Growth for Shareholders & Stakeholders
Delta-8 THC products have already proven to be one of CBDL's strongest performing categories, and this launch further solidifies the company's aggressive expansion in the high-growth cannabinoid edible space. The market for Delta-8 continues to gain national momentum, with sales projections showing compound annual growth that far outpaces many traditional supplement sectors.

"This gummy is just one part of a much larger product ecosystem we're building - focused on in-demand cannabinoids, real health outcomes, and market scalability," said Nelson.

Product Details

• Product: Delta-8 THC Gummy
• Type: Vegan, In-House Formulated, Lab-Tested
• MG per Gummy: 500MG
• Availability: Launching via www.thecbdvault.com
• Flavors: Blue Razz & Strawberry
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading